ARC101, a potential best-in-class T-cell engager that targets solid tumors expressing CLDN6, is being assessed in a ...

In cases presenting with massive ascites and high CA-125 levels without ovarian enlargement, clinicians should consider peritoneal TB as a potential diagnosis, alongside peritoneal carcinomatosis and ...

Becker, Ph.D. Paul Haluska, M.D. Palliation of ovarian cancer ascites via PAPP-A inhibition and repositioning antimalarial drug quinacrine to enhance carboplatin sensitivity in ovarian cancer View ...

Researchers at the University of Pittsburgh have identified a novel trigger for a deadly form of ovarian cancer: a subset of ...

Researchers at the University of Pittsburgh have identified a novel trigger of a deadly form of ovarian cancer: a subset of ...

A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer in a first-in-human trial. These results were presented at ...

Ovarian cancer is the deadliest form of gynecologic cancer, taking the lives of more than 13,000 women in the U.S. each year.

US-based pharmaceutical company AbbVie has reported the final analysis from the Phase III MIRASOL trial, which assessed its ...

ovarian cancer progressing under taxane/carboplatin chemotherapy or in early relapse (< 6 months).

Cancer that develops in the ovaries (the egg-producing reproductive organs) is referred to as ovarian cancer. There are three types of ovarian cancer. Each type has differences in how they will ...